Targeting the Tumour Vasculature: Exploitation of Low Oxygenation and Sensitivity to NOS Inhibition by Treatment with a Hypoxic Cytotoxin

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Baker, Jennifer H E ^a   Kyle, Alastair H ^a   Bartels, Kirsten L ^a   Methot, Stephen P ^a   Flanagan, Erin J ^a   Balbirnie, Andrew ^a   Cran, Jordan D ^a   Minchinton, Andrew I ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASE; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL DEATH; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; MOUSE; NONHUMAN; OXYGEN BREATHING; OXYGEN TENSION; OXYGENATION; SENSITIVITY ANALYSIS; SMOOTH MUSCLE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; ANOXIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYTOTOXINS; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C3H; MICE, INBRED NOD; MICE, SCID; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE; NITROARGININE; TREATMENT OUTCOME; TRIAZINES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886637380     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076832     Document Type: Article

References (50)

1. Thomlinson RH, Gray LH, (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539-549.
2. Dewhirst MW, (2003) Mechanisms underlying hypoxia development in tumors. Adv Exp Med Biol 510: 51-56.
3. Marcu L, Olver I, (2006) Tirapazamine: from bench to clinical trials. Current clinical pharmacology 1: 71-79.
4. Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA, (2005) Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. Org Biomol Chem 3: 2167-2174.
5. Brown JM, Lemmon MJ, (1990) Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50: 7745-7749.
6. Dorie MJ, Brown JM, (1993) Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53: 4633-4636.
7. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW, (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239-1242.
8. Bains LJ, Baker JH, Kyle AH, Minchinton AI, Reinsberg SA, (2009) Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 74: 957-965.
9. Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI, (2006) Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 78: 138-145.
10. Huxham LA, Kyle AH, Baker JH, McNicol KL, Minchinton AI, (2008) Exploring vascular dysfunction caused by tirapazamine. Microvasc Res 75: 247-255.
11. Siemann DW, (2011) The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 37: 63-74.
12. Thorpe PE, (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427.
13. Tozer GM, Kanthou C, Baguley BC, (2005) Disrupting tumour blood vessels. Nature Reviews Cancer 5: 423-435.
14. Boucher Y, Baxter LT, Jain RK, (1990) Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50: 4478-4484.
15. Baluk P, Hashizume H, McDonald DM, (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15: 102-111.
16. Tozer GM, Akerman S, Cross NA, Barber PR, Björndahl MA, et al. (2008) Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res 68: 2301-2311.
17. Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, et al. (2008) Tumour vascular disrupting agents: combating treatment resistance. The British journal of radiology 81 Spec No 1: S12-20.
18. Le QT, Fisher R, Oliner KS, Young RJ, Cao H, et al. (2012) Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res 18: 1798-1807.
19. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, et al. (2010) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28: 2989-2995.
20. Wouters BG, Delahoussaye YM, Evans JW, Birrell GW, Dorie MJ, et al. (2001) Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res 61: 145-152.
21. Garner AP, Paine MJ, Rodriguez-Crespo I, Chinje EC, Ortiz De Montellano P, et al. (1999) Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res 59: 1929-1934.
22. Patterson LH, McKeown SR, (2000) AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 83: 1589-1593.
23. Minchinton AI, Brown JM, (1992) Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing. Br J Cancer 66: 1053-1058.
24. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI, (2007) Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 13: 2804-2810.
25. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, et al. (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99: 683-690.
26. Leong KG, Hu X, Li L, Noseda M, Larrivée B, et al. (2002) Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol Cell Biol 22: 2830-2841.
27. Vaupel P, Mayer A, (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26: 225-239.
28. Fukumura D, Yuan F, Endo M, Jain RK, (1997) Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol 150: 713-725.
29. Horsman MR, Chaplin DJ, Hill SA, Arnold S, Collingridge D, et al. (1996) Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. Br J Cancer Suppl 27: S168-171.
30. Ng Q, Goh V, Milner J, Stratford M, Folkes L, et al. (2007) Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. The Lancet Oncology 8: 111-118.
31. Tozer GM, Prise VE, Chaplin DJ, (1997) Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 57: 948-955.
32. Dewhirst MW, Ong ET, Braun RD, Smith B, Klitzman B, et al. (1999) Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Br J Cancer 79: 1717-1722.
33. Fenton BM, Rofstad EK, Degner FL, Sutherland RM, (1988) Cryospectrophotometric determination of tumor intravascular oxyhemoglobin saturations: dependence on vascular geometry and tumor growth. J Natl Cancer Inst 80: 1612-1619.
34. Måseide K, Rofstad EK, (2001) Intratumour heterogeneity in microvessel oxyhaemoglobin saturations. Cancer Lett 162: 245-251.
35. Fukumura D, Kashiwagi S, Jain RK, (2006) The role of nitric oxide in tumour progression. Nature Reviews Cancer 6: 521-534.
36. Wood PJ, Sansom JM, Butler SA, Stratford IJ, Cole SM, et al. (1994) Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine. Cancer Res 54: 6458-6463.
37. Peters KB, Brown JM, (2002) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62: 5248-5253.
38. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA, (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624.
39. Gaboury JP, Anderson DC, Kubes P, (1994) Molecular mechanisms involved in superoxide-induced leukocyte-endothelial cell interactions in vivo. Am J Physiol 266: H637-642.
40. Stamler JS, (1994) Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 78: 931-936.
41. Butler SA, Wood PJ, Cole S, Williams C, Adams GE, et al. (1997) Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase. Br J Cancer 76: 438-444.
42. Cao Y, Li CY, Moeller BJ, Yu D, Zhao Y, et al. (2005) Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res 65: 5498-5505.
43. Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, et al. (2004) Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Res 64: 736-742.
44. Siim BG, Menke DR, Dorie MJ, Brown JM, (1997) Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 57: 2922-2928.
45. Elwell JH, Siim BG, Evans JW, Brown JM, (1997) Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem Pharmacol 54: 249-257.
46. Evans JW, Yudoh K, Delahoussaye YM, Brown JM, (1998) Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58: 2098-2101.
47. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, et al. (2008) Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 14: 2171-2179.
48. Steeg PS, Camphausen KA, Smith QR, (2011) Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 11: 352-363.
49. Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, et al. (2007) Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia 9: 128-135.
50. Graham MA, Senan S, Robin H, Eckhardt N, Lendrem D, et al. (1997) Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemotherapy and Pharmacology 40: 1-10.